Skip to main content

Table 1 Clinicopathological findings and correlation with miR-296 expression in CRC

From: miR-296 inhibits the metastasis and epithelial-mesenchymal transition of colorectal cancer by targeting S100A4

Features   n = 90 miR-296 expression P
    Low High  
Age (years) <65 59 30 (50.85%) 29 (49.15%) 0.824
≥65 31 15 (48.39%) 16 (51.61%)
Sex Male 48 26 (54.17%) 22 (45.83%) 0.398
Female 42 19 (45.24%) 23 (54.76%)
Tumor grade G1 + G2 67 35 (52.24%) 32 (47.76%) 0.468
G3 + G4 23 10 (43.48%) 13 (56.52%)
Size (cm) <5 30 17 (56.67%) 13 (43.33%) 0.371
≥5 50 28 (56.00%) 32 (44.00%)
Tumor invasion T1 + T2 22 5 (22.73%) 17 (77.27%) 0.003*
T3 + T4 68 40 (58.82%) 28 (41.18%)
Lymph node status <1 48 16 (33.33%) 32 (66.67%) 0.001*
≥1 42 29 (69.05%) 13 (30.95%)
Distant metastasis Absent 69 30 (43.48%) 39 (56.52%) 0.025*
Present 21 15 (71.43%) 6 (28.57%)
TNM stage I + II 43 16 (37.21%) 27 (62.79%) 0.020*
III + IV 47 29 (61.70%) 18 (38.30%)
  1. CRC colorectal cancer, TNM tumor-node-metastasis. * Statistically significant